About the webinar
As drug prices rise, so does the gross-to-net bubble — increasing rebate dollars without necessarily improving employer affordability. At the same time, policy changes, pricing transparency, and specialty drug expansion are putting new pressure on traditional PBM models.
In this webinar, brokers and employers will learn why the market is demanding a different kind of guarantee: one built on aligned incentives, integrated strategy, and accountable total cost of care outcomes.
Speaker
John Watson, PharmD
Chief Growth Officer
CarelonRx